RFA
BIOL

Reilly Financial Advisors’s Biolase, Inc. BIOL Stock Holding History

Reilly Financial Advisors’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8
Closed -$6K – 934
2020
Q3 		$6K Buy
+8
New +$7.5K ﹤0.01% 658

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $355M AUM 45.63% 1-Year Est. Return

Reilly Financial Advisors's BIOL Position: Q4 2020 in Review

Reilly Financial Advisors sold out of Biolase, Inc. (BIOL) in Q4 2020, closing a stake of 8 shares — an estimated $6K sold.

Reilly Financial Advisors first reported a position in BIOL in Q3 2020 and held it in 1 quarter. The position peaked at $6K in Q3 2020. 29 funds tracked by Wall St. Rank hold BIOL as of Q4 2020.

  • Reilly Financial Advisors reported no remaining Biolase, Inc. position as of Q4 2020 after selling out during the quarter.
  • Reilly Financial Advisors sold 8 Biolase, Inc. shares in Q4 2020, an estimated $6K.
  • Reilly Financial Advisors first reported a position in Biolase, Inc. in Q3 2020 and held it in 1 quarter.
  • Reilly Financial Advisors's Biolase, Inc. position peaked at $6K in Q3 2020.
  • 29 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2020.

Based on Reilly Financial Advisors's 13F filing for Q4 2020, filed 3 Feb 2021.